Newsfeed

Systemic Sclerosis Patients At Higher Risk To Develop PAH
A team of over twenty researchers recently found that patients with systemic sclerosis are at high risk to develop pulmonary arterial hypertension(PAH). The study, published in the Seminars in Arthritis & Rheumatism, set out to understand the natural history of pulmonary hypertension (PH) in systemic sclerosis (Ssc), through a prospective longitudinal cohort study they called Pulmonary Hypertension Assessment and Recognition of Outcomes in Scler…
Tom Lantos Innovation in Community Service Awards Given by Pulmonary Hypertension Association to Advance Awareness of Rare Lung Disease
The Pulmonary Hypertension Association (PHA) has awarded 13 committed community activists funding for projects to raise awareness of pulmonary hypertension (PH) – a rare, debilitating disease of the lungs that affects the functioning of the heart and can lead to right heart failure. Without treatment, mean survivability is only 2.8 years. Known as the Tom Lantos Innovation in Community Service Awards, the grants were established to create opport…
Pulmonary Hypertension in Infants: Subcutaneous Treprostinil?
Subcutaneous treprostinil (SCTre) is an effective second-line therapy for former premature infants who have chronic lung disease and severe pulmonary hypertension, according to Dina J. Ferdman, MD, from the Division of Pediatric Cardiology, Department of Pediatrics, Columbia University Medical Center, College of Physicians and Surgeons, New York City, and colleagues. They published the results of their case series of 5 infants online June 30 and …
Severe pulmonary arterial hypertension secondary to lupus in the emergency department: Proactive intense care associated with a better short-term survival
Chen Y, et al. – The aim of the current prospective study is to initiate a proactive intense care strategy on severe systemic lupus erythematosus (SLE)–PAH patients in the emergency setting and evaluate its impact on the short–term survival. Therefore, the study suggest that proactive care and combination PAH–targeted treatment can improve short–term survival of severe SLE–PAH in the emergency setting. Methods The proactive intense care str…
Hidden Origins Of Pulmonary Hypertension Revealed by Network Modeling
In a groundbreaking study, researchers from Brigham and Women’s Hospital (BWH) have identified a related family of molecules believed to be a major root cause of pulmonary hypertension, a deadly vascular disease with undefined origins. This is one of the first studies to leverage advanced computational network modeling to decipher the molecular secrets of this complex human disease. The study is published online June 24, 2014 in The Journal of…
Gender–dependent Influence of Endogenous Estrogen in Pulmonary Hypertension.
Abstract Rationale: The incidence of pulmonary arterial hypertension (PAH) is greater in women suggesting estrogens may play a role in the disease pathogenesis. Experimentally, in males exogenously administered estrogen can protect against PH; however in models that display female susceptibility estrogens may play a causative role. Objectives: To clarify the influence of endogenous estrogen and gender in PH and assess the therapeutic potential o…
Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study in patients with pulmonary arterial hypertension
ALLSCHWIL, SWITZERLAND - 16 June 2014 - Actelion Ltd (six:ATLN) today announced the top-line results of the pivotal Phase III GRIPHON study in 1,156 patients with pulmonary arterial hypertension (PAH) with selexipag, the first selective oral prostacyclin IP receptor agonist. Initial analysis shows that the event-driven outcome study has met its primary efficacy endpoint with high statistical significance. Selexipag decreased the risk of a morb…
Bayer Tests Riociguat to Treat Symptomatic Pulmonary Hypertension
Bayer HealthCare recently announced it will test the efficacy and safety of the drug Riociguat in patients with symptomatic pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP). The study will take place at more than 50 sites in 11 countries and will include about 120 patients. Designed as signal-generating, the trial intends to improve knowledge about the disease and the drug’s effect on it. The RISE-IIP is a ran…
Reata Enrolls First Patient In Promising, New Pulmonary Arterial Hypertension Trial
Irving-based Reata Pharmaceuticals, a privately held company aiming to translate the company’s groundbreaking research into new therapies, has enrolled the first patient in a Phase 2 dose-ranging study that will examine the safety, tolerability, and efficacy of bardoxolone methyl in patients with pulmonary arterial hypertension (PAH). Pulmonary hypertension involves high blood pressure in the arteries of the lungs. The American Lung Association …
Bayer Trial Will Evaluate Riociguat in New Indication
Bayer HealthCare announced the start of a randomized, double-blind, placebo-controlled Phase 2b study. The RISE-IIP study (Riociguat in Patients with Symptomatic Pulmonary HypErtension associated with Idiopathic Interstitial Pneumonias) is designed to investigate the efficacy and safety of riociguat in patients with symptomatic pulmonary hypertension (PH) associated with idiopathic interstitial pneumonia (IIP). Pulmonary hypertension is a co-…
Recent News

Subscribe

Get the latest on PH treatments, community events and more when you subscribe to our newsletter

ImagineCan_Accreditation_Trustmark_ENGFR_WHT-FNL_white.png